The stock of Sera Prognostics Inc (SERA) has seen a -3.17% decrease in the past week, with a 21.56% gain in the past month, and a 3.25% flourish in the past quarter. The volatility ratio for the week is 8.13%, and the volatility levels for the past 30 days are at 7.51% for SERA. The simple moving average for the past 20 days is 3.27% for SERA’s stock, with a 0.27% simple moving average for the past 200 days.
Is It Worth Investing in Sera Prognostics Inc (NASDAQ: SERA) Right Now?
SERA has 36-month beta value of 0.88. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SERA is 21.30M, and currently, short sellers hold a 4.17% ratio of that float. The average trading volume of SERA on December 26, 2024 was 92.43K shares.
SERA) stock’s latest price update
The stock price of Sera Prognostics Inc (NASDAQ: SERA) has dropped by -7.56 compared to previous close of 8.60. Despite this, the company has seen a fall of -3.17% in its stock price over the last five trading days. prnewswire.com reported 2024-12-04 that SALT LAKE CITY, Dec. 4, 2024 /PRNewswire/ — Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium presentation at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting™ on January 31, 2025 at 10:15 a.m. MT. Dr. Brian Iriye – maternal-fetal medicine expert at the High Risk Pregnancy Center in Las Vegas, Nevada, and principal investigator for the PRIME study – will present the results of the full PRIME study.
Analysts’ Opinion of SERA
Many brokerage firms have already submitted their reports for SERA stocks, with Citigroup repeating the rating for SERA by listing it as a “Neutral.” The predicted price for SERA in the upcoming period, according to Citigroup is $4 based on the research report published on March 30, 2022 of the previous year 2022.
Oppenheimer, on the other hand, stated in their research note that they expect to see SERA reach a price target of $19. The rating they have provided for SERA stocks is “Outperform” according to the report published on November 19th, 2021.
SERA Trading at 7.99% from the 50-Day Moving Average
After a stumble in the market that brought SERA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.65% of loss for the given period.
Volatility was left at 7.51%, however, over the last 30 days, the volatility rate increased by 8.13%, as shares surge +24.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.03% upper at present.
During the last 5 trading sessions, SERA fell by -3.17%, which changed the moving average for the period of 200-days by -13.87% in comparison to the 20-day moving average, which settled at $7.70. In addition, Sera Prognostics Inc saw 32.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SERA starting from Lindgardt Zhenya, who proposed sale 26,224 shares at the price of $7.41 back on Dec 10 ’24. After this action, Lindgardt Zhenya now owns shares of Sera Prognostics Inc, valued at $194,396 using the latest closing price.
Aerts Austin, the Officer of Sera Prognostics Inc, proposed sale 5,730 shares at $7.41 during a trade that took place back on Dec 10 ’24, which means that Aerts Austin is holding shares at $42,476 based on the most recent closing price.
Stock Fundamentals for SERA
Current profitability levels for the company are sitting at:
- -382.37 for the present operating margin
- -7.83 for the gross margin
The net margin for Sera Prognostics Inc stands at -343.02. The total capital return value is set at -0.66. Equity return is now at value -49.58, with -38.15 for asset returns.
Currently, EBITDA for the company is -35.29 million with net debt to EBITDA at 0.05. When we switch over and look at the enterprise to sales, we see a ratio of 2757.59. The receivables turnover for the company is 1.19for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.11.
Conclusion
To put it simply, Sera Prognostics Inc (SERA) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
